{
    "clinical_study": {
        "@rank": "122607", 
        "arm_group": {
            "arm_group_label": "Pentoxifylline", 
            "arm_group_type": "Other", 
            "description": "effect of pentoxifylline on ICSI outcome"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the effect of pentoxifylline used in preparation of semen samples that will be\n      used for ICSI in infertile men complaining of mild and moderate asthenozoospermia (i.e.\n      cases which does not need motility enhancement prior to ICSI) in comparison to semen samples\n      without pentoxifylline preparation on the outcome of ICSI."
        }, 
        "brief_title": "Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": "Pentoxifylline Allergy", 
        "detailed_description": {
            "textblock": "The primary outcome measures were the number of oocytes retrieved, the number of oocytes\n      injected, number of oocytes fertilized, fertilization rate, number of embryos and their\n      quality (G1: good embryos, G2: fair embryos and G3: bad embryos), number of embryos\n      transferred (ET), number of embryo sacs, embryo implantation rate, pregnancy rate and\n      abortion rate for all 3 groups and pregnancy rate and abortion rate for both group (I) and\n      group (II)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  seeking ICSI for infertility\n\n        Exclusion Criteria:\n\n          -  Pyospermia, presence of antisperm antibodies. Azoospermia, severe male factor, severe\n             asthenozoospermia. Past history of orchitis. Patients who received empirical\n             treatment for asthenozoospermia e.g. oral Pentoxifylline, l-carnitine or antioxidants\n             during the past 3 to 6 month. Diabetics, hypertensives or patients with any other\n             chronic systemic illnesses. Wife's age more than 35 years. Low antral count. Presence\n             of any ovarian factor contributing to infertility e.g. polycystic ovaries."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793272", 
            "org_study_id": "11-2-13"
        }, 
        "intervention": {
            "arm_group_label": "Pentoxifylline", 
            "description": "semen processing with pentoxifylline prior to ICSI", 
            "intervention_name": "effect of pentoxifylline on ICSI outcome", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentoxifylline"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Giza", 
                    "country": "Egypt", 
                    "zip": "12411"
                }, 
                "name": "Adam International Hospital"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "1", 
        "official_title": "Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males With Mild and Moderate Asthenozoospermia: Randomized Controlled Prospective Crossover Study", 
        "overall_official": {
            "affiliation": "M.Amer", 
            "last_name": "Medhat Amer, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "ICSI outcome", 
            "safety_issue": "Yes", 
            "time_frame": "from October 2010 to April 2011."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793272"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Adam International Hospital", 
            "investigator_full_name": "Ahmad Raef Sadek", 
            "investigator_title": "Ahmad Raef", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Adam International Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adam International Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}